Apimeds Pharmaceuticals US, Inc. 10-Q filing
Filed 2026-05-26 · Report date 2026-03-31 · 2026
Filing metadata
- Accession number
- 0001213900-26-061013
- Form type
- 10-Q
- CIK
- 0001894525
- Primary document
- https://www.sec.gov/Archives/edgar/data/1894525/000121390026061013/ea0291982-10q_apimeds.htm
Extracted primary information
This filing includes deterministic financial metrics extracted from public filing data for Apimeds Pharmaceuticals US, Inc..
Reported financial metrics
| Metric | Current | Prior | Change |
|---|---|---|---|
| Operating Income | $-12.2M | - | - |
| Net Income | $-35.1M | - | - |
| Eps Basic | -2.26 | - | - |
| Eps Diluted | -2.26 | - | - |
| Cash And Equivalents | $979,534 | - | - |
| Total Assets | $141.2M | - | - |
| Total Liabilities | $14.7M | - | - |
| Shareholders Equity | $126.5M | - | - |
| Operating Cash Flow | $-2.1M | - | - |
| Capital Expenditures | $9,394 | - | - |